158 related articles for article (PubMed ID: 36182722)
1. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
[TBL] [Abstract][Full Text] [Related]
2. [Pre-Transfusion Testing and Transfusion Strategy in Patients with Multiple Myeloma after Daratumumab Treatment].
Fang XM; Guo ZW; Yang JQ; Yang B; Xiao YH; Liu Y; Xu ML
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1595-1600. PubMed ID: 34627446
[TBL] [Abstract][Full Text] [Related]
3. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
[TBL] [Abstract][Full Text] [Related]
4. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
[TBL] [Abstract][Full Text] [Related]
5. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of Low Concentration Dithiothreitol for Negating the Monoclonal Anti-CD38 Interference with Transfusion Compatibility Testing].
Song J; Chen Li YH; Liu AP; Wang SY; Lyu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1198-1202. PubMed ID: 35981384
[TBL] [Abstract][Full Text] [Related]
7. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
[TBL] [Abstract][Full Text] [Related]
8. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
Ye Z; Wolf LA; Mettman D; Plapp FV
Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
[TBL] [Abstract][Full Text] [Related]
9. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
10. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests.
Zhou Y; Chen L; Jiang T; Fan L; Lei H; Wang Y; Heililahong H; Mi J; Du D; Miao T; Xia R; Wang X; Xiang D; Cai X; Tang X
Hematology; 2021 Dec; 26(1):365-370. PubMed ID: 33971806
[TBL] [Abstract][Full Text] [Related]
11. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
[TBL] [Abstract][Full Text] [Related]
13. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
[TBL] [Abstract][Full Text] [Related]
14. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
[TBL] [Abstract][Full Text] [Related]
15. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
De Vooght KM; Oostendorp M; van Solinge WW
Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
[TBL] [Abstract][Full Text] [Related]
16. Transfusion management for patients taking an anti-CD38 monoclonal antibody.
Bub CB; Reis IND; Aravechia MG; Santos LD; Bastos EP; Kutner JM; Castilho L
Rev Bras Hematol Hemoter; 2018; 40(1):25-29. PubMed ID: 29519368
[TBL] [Abstract][Full Text] [Related]
17. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
Transfusion; 2024 May; ():. PubMed ID: 38767410
[TBL] [Abstract][Full Text] [Related]
18. The Challenges of Daratumumab in Transfusion Medicine.
Dizon MF
Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
[TBL] [Abstract][Full Text] [Related]
19. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.
Izaguirre EC; Del Mar Luis-Hidalgo M; González LL; Castaño CA
Blood Transfus; 2020 Jul; 18(4):290-294. PubMed ID: 32530397
[TBL] [Abstract][Full Text] [Related]
20. [Application of Modified DTT Methods to Reduce the Interference of Daratumumab on Serological Detection].
Li YY; Zhang L; Cai K; Wu MH; Zhu LR; Li CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1543-1549. PubMed ID: 37846714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
